Objective This study utilizes network pharmacology and molecular docking techniques to explore the role of colchicine in regulating ferroptosis for the treatment of neurological injury. Methods Colchicine targets were obtained from the PubChem and Swiss Target Prediction databases, while targets related to neurological injury were retrieved from the GeneCards, OMIM, and DisGeNET databases. Ferroptosis targets were sourced from the FerrDb database, and the Venny 2.1.0 tool was accustomed to identify the intersection of these three sets. A protein-protein interaction (PPI) network was constructed based on the STRING database, and GO and KEGG pathway enrichment analyses were conducted using Metascape. Ultimately, molecular docking analyses of colchicine with the top ten targets were performed using Autodock Vina. Results There were 401 targets for colchicine, 3 367 for neurological injury, and 1 543 for ferroptosis, with 57 intersection targets. The PPI network identified TP53, IL6, EGFR, and others as major targets. KEGG analysis indicated that colchicine regulated ferroptosis through the Wnt signaling pathway to treat neurological injury. Molecular docking results showed that colchicine bound well to multiple targets. Conclusion Colchicine may regulate related genes through the Wnt signaling pathway to treat neurological injury.

Objective To observe the clinical effect of the treatment of traumatic lacrimal canalicular laceration with single canalicular artificial lacrimal duct and double canalicular artificial lacrimal duct. Methods Sixty patients (60 eyes) with lacrimal canalicular laceration who visited the Department of Ophthalmology, Affiliated Hospital of Chengde Medical University the first time from March 2017 to December 2021 were selected. According to different surgical methods, patients were divided into group A(27 patients )and group B(33 patients). Group A was treated with single canalicular placement of artificial lacrimal duct for canalicular laceration anastomosis, and group B was treated with double canalicular placement of artificial lacrimal duct for canalicular laceration anastomosis. After 6 months ,we compared the patency of lacrimal passage and complications between the two groups. Results The cure rate of group A was 48.15%(13/27) and that of group B was 81.82%(27/33). There was significant difference between the two groups (P<0.05). Conclusion The treatment of lower lacrimal canalicular laceration with double canaliculi implantation artificial lacrimal duct is effective, the reduction of lacrimal canaliculi is closer to the anatomical structure, and there are few complications. It is an ideal surgical method for the treatment of traumatic lower lacrimal canalicular laceration.

Objective To evaluate the risk factors of hepatic encephalopathy in patients with cirrhosis. Methods Retrieve database both at home and abroad, collecting the relevant risk factors in patients with cirrhosis of the liver encephalopathy of case-control study, retrieval time limit are built from library to December 31, 2020, after finishing the document screening and quality evaluation software application Revman5.4 meta-analysis. Results A total of 9 papers with 1569 patients were included in this study, involving 10 risk factors, of which high heterogeneity in serum albumin and blood creatinine was not subjected to Meta-analysis.Serum ammonia, infection, upper gastrointestinal hemorrhage, ascites, serum total bilirubin, prothrombin time, urea nitrogen and serum natrium are risk factors for hepatic encephalopathy in patients with cirrhosis (P<0.05). Conclusion Elevated serum ammonia level, infected, upper gastrointestinal bleeding, ascites, serum total bilirubin level increased, prothrombin time prolonged, serum sodium level decreased and blood urea nitrogen increased are risk factors for hepatic encephalopathy in patients with cirrhosis, serum albumin levels and serum creatinine levels were uncertain.

Objective: To study the effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Erlotinib on curative effects and survival rate of non-small cell lung cancer (NSCLC) patients with different mutants of EGFR gene. Methods: 72 cases of advanced NSCLC patients with EGFR positive mutations were divided into study group (n=33) and control group (n=39) according to mutations in exon 19 or 21 of EGFR gene. All the patients were treated with Erlotinib Hydrochloride Tablets orally till disease progression or death. The short-term clinical effective rate, time to progression (TTP) and one-year survival rate of patients in 2 groups were compared. Results: The short-term clinical effective rate, one-year survival rate and average TTP of patients in study group were all obviously higher than control group (P<0.05). Conclusions: The curative effects and survival rate of NSCLC patients with exon 19 mutation were better than NSCLC patients with exon 21 mutation when treating NSCLC with EGFR-TKI Erlotinib. Which suggests that detection of different mutants of EGFR gene may be helpful in formulating individualized therapeutic regimen and predicting the therapeutic effect of EGFR-TKI Erlotinib.